Clinical experience with recently approved antibiotics

Paterson, David L. (2006) Clinical experience with recently approved antibiotics. Current Opinion in Pharmacology, 6 5: 486-490. doi:10.1016/j.coph.2006.07.001


Author Paterson, David L.
Title Clinical experience with recently approved antibiotics
Journal name Current Opinion in Pharmacology   Check publisher's open access policy
ISSN 1471-4892
1471-4973
Publication date 2006-10-01
Sub-type Article (original research)
DOI 10.1016/j.coph.2006.07.001
Volume 6
Issue 5
Start page 486
End page 490
Total pages 5
Editor N. G. Bowery
T. P. Kenakin
Place of publication New York, N.Y. U.S.A.
Publisher Elsevier
Language eng
Subject 1115 Pharmacology and Pharmaceutical Sciences
1103 Clinical Sciences
Abstract The advent of vancomycin-resistant enterococci in the 1990s and the threat posed by vancomycin resistance in Staphylococcus aureus led to the development of several new antimicrobial agents active against these pathogens. Quinupristin/dalfopristin was the first such drug to be commercially available but adverse effects have meant that the drug is now rarely used. Linezolid, the first antimicrobial of the oxazolidinone class, has met with more widespread use and has both an intravenous and an oral formulation. Daptomycin is a lipopeptide antimicrobial that is rapidly bactericidal against S. aureus. It is effective in the therapy of S. aureus bloodstream infections but is inactivated by pulmonary surfactant, making it of no use in the therapy of pneumonia. Tigecycline, by contrast, is bacteriostatic against most pathogens but has a broad spectrum of antimicrobial activity and has enhanced penetration into many tissues. Other new antibiotics (dalbavancin, telavancin, ceftobiprole and doripenem) are currently under clinical development and hold promise for widespread clinical use in the next decade. Copyright © 2010 Elsevier B.V. All rights reserved.
Keyword Acetamides
Anti-bacterial agents
Bacterial infections
Daptomycin
Minocycline
Oxazolidinones
Staphylococcal infections
Streptococcal infections
Virginiamycin
Q-Index Code C1

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
UQ Centre for Clinical Research Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 37 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 49 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 22 Jan 2010, 21:33:14 EST by Kelly Whitehorne on behalf of Faculty Of Health Sciences